Youtube
CIPLA

Cipla Ltd.

₹970.4

Score

56

Technically Neutral

Advice

Cipla Price Change Analysis

Cipla Key Statistics
  • P/E Ratio

    26.5

  • PEG Ratio

    6.7

  • Market Cap Cr

    78293.2

  • Price to Book Ratio

    279

  • EPS

    36.7

  • Dividend

    0 ()

  • Relative Strength Index

    51.79

  • Money Flow Index

    49.08

  • MACD Signal

    -14.33

  • Average True Range

    25.43

Investment Ratings

  • Master Rating:

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Cipla Synopsis

NSE-Medical-Generic Drugs

Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13091.79 Cr. and Equity Capital is Rs. 161.36 Cr. for the Year ended 31/03/2022. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
  • Market Cap

    78,261.00

  • Sales

    14,853.84

  • Shares in Float

    54.06

  • No of Funds

    1210

  • Yield

    0.52

  • Book Value

    3.48

  • U/D Vol Ratio

    1.4

  • LTDebt/Equity

  • Alpha

    0.02

  • Beta

    0.23

Cipla Ownership
Cipla Management

Cipla Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Cipla Financials

Cipla Technicals

EMA & SMA

CURRENT PRICE

EMA

Cipla Resistance and Support

Cipla Delivery and Volume

Cipla Price Change Analysis

Corporate Action

MF Shareholding

Similar Stocks

Videos

About Company

News

FAQs

Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

Umang Vohra has been the CEO of Cipla since 1 September 2016.

Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

Open Demat Account